When a doctor suggests looking at cancer instead of treating it right away, it’s normal to feel hesitant or uneasy. Even so, in certain scenarios, active cancer monitoring: in which cases to watch closely can be part of the plan and not an omission does not mean “letting time pass”, but following a well-supported clinical strategy, with strict controls and adjusted to each patient. Being clear about when it applies can make a big difference in quality of life.
What is Active Monitoring in Cancer Treatment?
Active monitoring is a structured approach in which the doctor decides not to start immediate treatment —such as surgery or radiation therapy—and instead follows the tumor’s behavior closely and regularly.
Difference Between Active Surveillance and Watchful Waiting
Although they sound similar, they do not mean the same thing. Active surveillance seeks to cure the cancer if it progresses; That’s why it includes regular screenings, biopsies, and defined criteria for deciding when to intervene. Watchful waiting, on the other hand, is often considered in older patients or those with limited life expectancy, where the primary goal is to control symptoms rather than seek a cure. According to the American Cancer Society, this difference is key to choosing the right path according to the profile of each patient.
Active surveillance as a therapeutic strategy
Active surveillance is not a waiver of treatment. It involves constant and careful medical follow-up. Its goal is to avoid the late effects of interventions that might be unnecessary — such as erectile dysfunction or incontinence — on tumors that statistically may not progress for years.
When Active Surveillance Is Recommended
Not all cancers need to be treated right away. This strategy is usually indicated when the tumour is low risk and early diagnosis allows its behaviour to be anticipated with some precision.
Criteria in Early-Stage Prostate Cancer
Early-stage prostate cancer is the context where this strategy is most studied and applied. The most common criteria include: prostate-specific antigen less than 10 ng/mL, tumor confined to the prostate, absence of relevant symptoms, and life expectancy greater than ten years. The National Cancer Institute of the United States points out that many men with low-risk prostate cancer die from other causes without the tumor having been a real threat.
Gleason Rating and Other Low-Risk Indicators
The Gleason classification is a diagnostic tool that assesses how aggressive the tumor tissue looks under a microscope. In general, a score of 6 or less is associated with well-differentiated and slow-growing tumors, making them frequent candidates for active surveillance. This scale, along with the prostate-specific antigen and the number of positive cores on the prostate biopsy, helps guide the clinical decision.
Early diagnosis and disease progression
An early diagnosis does not always automatically lead to immediate treatment. In many cases, it allows the identification of tumours with such a slow progression of the disease that intervening could cause more harm than good. It is precisely in this space that active surveillance makes clinical sense.
How the Active Surveillance Protocol Works
Active surveillance is not left to chance: it is supported by a protocol with periodic controls and clear criteria to act if the condition changes.
Regular screenings: prostate-specific antigen and digital rectal exam
Follow-up is mainly based on the periodic measurement of prostate-specific antigen in the blood. If levels rise steadily or rapidly, it may be a sign of progression. Digital rectal examination, when deemed useful by the physician based on the patient’s medical history, complements the evaluation by detecting changes in the size or consistency of the gland.
Prostate biopsies and follow-up for signs of progression
Biopsies are a central part of the protocol. They are done on a scheduled basis — usually every one to three years — to confirm if the histologic signs of the tumor have changed. If a prostate biopsy shows more aggressiveness, it may be time to move on to active treatment.
Use of MRI and CT scans
Multiparametric magnetic resonance imaging allows you to see the tumor in more detail, reduce unnecessary biopsies, and more accurately locate suspicious areas. CT scans are used to assess whether there is extension to neighboring nodes or organs. These tools have significantly improved the ability to differentiate between tumors that require intervention and those that do not. According to a study published in the New England Journal of Medicine, pre-biopsy MRI reduces the detection of clinically non-significant cancers.
What Tests Are Performed and How Often
Personalized follow-up care plan
Each patient needs a different follow-up care plan, adjusted to their age, previous results, family history and risk profile. Dr. Roberto García, a specialist in Oncology and Oncological Surgery in Panama, works with an individualized approach: he indicates the tests according to the risk of each person, not by routine, and accompanies the patient in the interpretation of each result so that decisions are clear and shared.
Typical schedule of controls and analyses
A common schedule may include: prostate-specific antigen measurement every three to six months for the first two years, and then annually if values remain stable; annual digital rectal exam when applicable; magnetic resonance imaging every one to three years; and prostate biopsy every one to two years or if any relevant changes appear.
Signs of Progression: When to Move from Surveillance to Active Treatment
Symptoms and signs that indicate a change in strategy
There are symptoms or signs that should be checked for promptly: rapid increase in prostate-specific antigen, changes in the Gleason classification on biopsy, tumor growth seen on imaging, or the appearance of new urinary symptoms. Any of these findings may indicate that the tumor has evolved and that active surveillance is no longer enough.
Transition to active therapies
When data suggest progression, the treatment summary is adjusted. The medical team evaluates options such as surgery, radiotherapy or other therapies depending on the stage reached. This transition is made in a planned manner, which represents an advantage over detecting a progression of the tumour without having had follow-up. This transition is done in a planned way.
Benefits and Risks of Active Cancer Monitoring
Advantages: avoiding late effects of unnecessary treatment
Active surveillance helps avoid exposing the patient to late effects of treatments they may not need: urinary, sexual, or bowel problems that can permanently affect quality of life. In low-risk tumors, this strategy offers similar oncological results to be treated immediately, with less burden on the body.
Considerations: Anxiety and Ongoing Medical Care
Living with a cancer diagnosis under supervision can generate anxiety. Therefore, emotional support and clear communication with the treating physician are essential to sustain the process. In this approach, ongoing medical care is not optional — it’s the foundation of the plan.
Frequently Asked Questions about Active Surveillance
¿El monitoreo activo significa no hacer nada contra el cáncer?
It means maintaining a rigorous and orderly follow-up. Screenings, biopsies, and imaging checks are performed on a regular basis, and intervention is performed as soon as signs of progression appear.
¿Para qué tipos de cáncer funciona esta estrategia?
It is mainly applied in low-risk prostate cancer . It is also studied in some cases of thyroid cancer, kidney cancer and chronic lymphocytic leukemia, although with different criteria depending on the type of tumour.
¿Qué preguntar al médico antes de optar por vigilancia activa?
It may help to ask: what is the Gleason classification of my tumor?, how often do I need checkups?, what signs should I report between appointments?, when should I switch to active treatment? And what late effects would the treatment have if I decide to do it now?
If you have a recent diagnosis or doubts about the follow-up of your case, Dr. Roberto García, a specialist in Oncology and Oncological Surgery, attends The Panama Clinic, in Panama. You can contact 6545-6968 to schedule a consultation and receive clear, personalized and unhurried guidance.
Content reviewed by Dr. Roberto García, specialist in Oncology and Oncological Surgery.
The key to active cancer monitoring: in which cases to closely monitor can be part of the plan and not an omission is to do it with defined controls and constant medical accompaniment.
